Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. - Wikidata - awgldk - TriplyDB

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

http://www.wikidata.org/entity/Q42791258

about

Pharmacokinetic/pharmacodynamic modeling in inflammation X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.Insulin-like growth factor-2 enhances functions of antigen (Ag)-specific regulatory B cells.Inhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in rats Advances in kinase inhibition: treating rheumatic diseases and beyond.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma Prolonged and tunable residence time using reversible covalent kinase inhibitors.The ins and outs of selective kinase inhibitor development.A unique role for ITK in survival of invariant NKT cells associated with the p53-dependent pathway in mice.Tyrosine kinase Btk is required for NK cell activation Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study Tec family kinases in inflammation and disease.The role of the tec kinase Bruton's tyrosine kinase (Btk) in leukocyte recruitment.BMX and its role in inflammation, cardiovascular disease, and cancer.Novel small molecule therapeutics in rheumatoid arthritis.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).Aberrant B cell selection and activation in systemic lupus erythematosus.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Ibrutinib and novel BTK inhibitors in clinical development.Emerging immunotherapies for rheumatoid arthritis.

P2860

Q26830621-6216FE03-7253-46B6-97BF-8C81128C22F7 Q27672770-51F6511C-45EE-49C4-8D14-947AD2457163 Q27686770-1719D6E8-607F-4BEE-AB91-822C04297D3E Q30008736-0376E0A5-268D-4A03-8FD4-CB528B6F405B Q30009224-DBF5E0BA-5718-4C02-8E04-756FB8916914 Q33636442-1CB48235-F728-465F-BC29-124247758D0E Q33653945-EF24A8F3-BADD-4876-BBE6-A4C4F34C77E3 Q33774517-92221A70-0C3F-4D62-A92A-DCF12DEC6B46 Q33786371-E65FA270-2E89-451A-A6FA-F4DFEC1FD9FC Q33793070-6BE04433-9EAE-4613-B937-C21ACFF51213 Q33827989-BB485518-2E0D-42EC-B55A-FC9FD5A58FF4 Q33930795-875A21C8-A049-4689-915B-27C5E4B5CC29 Q34039406-4C264C2D-AB6B-4E8C-B940-E6FC052A5089 Q35181271-43F74359-8B64-4552-8D43-59791D92590F Q35260732-4A88E4DF-89F7-4B38-BB75-3027A9F24749 Q35756228-11B682F0-6EB3-4A46-909A-E9D9FB8F11FC Q35814547-6EA6AD78-170B-4AD1-BCEE-DF40B46B4B18 Q35915693-8C047A9B-FA60-4B97-A1FB-0B7BFB3B3B2F Q36078834-6BD01347-C44C-4043-A2B2-B920BB82B8D4 Q36190423-1321F39F-C68F-447F-BBD6-FA805F4416F3 Q36206430-98D8887A-4ED7-48E7-9756-A2F4251BB607 Q36240548-6302309F-C84A-4F20-B2A1-8571A1F19663 Q36517276-8DC5D8CC-C749-4C76-AC5E-523333C799F4 Q36548443-3F4935BF-F8D8-4576-B344-3F0E084C6370 Q36810546-266931DE-9A36-4E17-8140-F4D5B1985A22 Q36907698-4495302D-0C18-4BDF-BDE9-7F93CC750F7D Q37671216-8EA97571-89AD-4F90-8919-348867AF083B Q37678085-0F1F58E1-97D8-4EB1-B337-E10058878E7F Q37730801-59642F05-BB64-4415-AF92-A1F6701CA1D3 Q37744817-ECFA8AC9-5321-4ADC-B570-20E16D298C41 Q37997073-E0B2A709-8293-40A7-894E-134164B20BEF Q37997074-77E362FF-0B48-41D2-BB01-4A81EAF19AD0 Q37997079-C58AE087-E293-43FF-B095-E8991A75A023 Q38072417-A4086827-1A28-4C16-88D9-C37074078B72 Q38083077-030AF081-3007-48F2-B7EA-116BBF2B4985 Q38114501-62DB5912-C8E9-4B05-A172-5D3CA0A9A7E2 Q38124119-E518269E-3F5D-457B-8C26-3B27B61E52AD Q38124120-8AA69F8A-AFBB-45DA-9AB6-14DE029EB29F Q38130010-98E6860E-986F-4346-9F96-588BCD49374B Q38188862-4EACBCC1-09DC-425A-A399-24FBD094E7BA

P2860

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

http://www.wikidata.org/entity/Q42791258

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@en

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@nl

type

label

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@en

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@nl

prefLabel

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@en

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@nl

P1433

Q42791258-2B600CC9-EE8D-419F-87A2-1402E72FE4E0

P1476

Q42791258-A2D055CB-3124-4E6E-AB45-3436C0DA140D

P2093

Q42791258-0715B4D0-7131-45C0-92EA-0405F4A3AB9E

Q42791258-10137FA5-F768-44F2-BA0F-2F2F6DD190F9

Q42791258-123BF738-A19E-41BA-B5B0-46BEF44A456C

Q42791258-2423148B-E962-4FA0-BC64-7FFA75B4E05A

Q42791258-2698B9D6-10DD-42A4-AC8F-8A87E1180AAC

Q42791258-27FC1983-6964-4922-B5F6-887393904E5D

Q42791258-2CC78515-99CC-4DEB-B779-5497CF89B427

Q42791258-3D866CA2-BB72-4910-9025-5AE8AE853411

Q42791258-3F0389CD-7333-435D-8E56-C98B1C4963AD

Q42791258-403418C0-7E19-49D8-9903-2FDA656C8860

P2888

Q42791258-DE41F823-3D4B-4B15-9D49-4378C7AA0799

P304

Q42791258-F2C05EEF-B604-4843-B318-52EBC48C6360

P31

Q42791258-C7AEB203-A9C3-45BC-9E44-24F4241169D6

P356

Q42791258-EF25B306-48CA-4CB2-8FBE-5152EA4690FE

P433

Q42791258-3CFF21BC-44A8-4710-9777-97D8DF170E76

P478

Q42791258-3A3BFE6F-3750-4D82-B89C-58C35114D780

P577

Q42791258-22279E55-7193-4C19-971F-3BCF50AB7B52

P6179

Q42791258-A617FB20-CA52-4530-8E11-7048981F437F

P698

Q42791258-EBDE4FAD-7768-4C1B-82AA-6BACC6B639D9

P356

P1433

Nature Chemical Biology

P1476

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

@en

P2093

Anthony M Giannetti

http://www.w3.org/2001/XMLSchema#string

Bart L Staker

http://www.w3.org/2001/XMLSchema#string

Brandon J Bravo

http://www.w3.org/2001/XMLSchema#string

Christine Yu

http://www.w3.org/2001/XMLSchema#string

Douglas R Davies

http://www.w3.org/2001/XMLSchema#string

Hong Rong

http://www.w3.org/2001/XMLSchema#string

J Andrew Whitney

http://www.w3.org/2001/XMLSchema#string

James Barbosa

http://www.w3.org/2001/XMLSchema#string

James Darrow

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Kropf

http://www.w3.org/2001/XMLSchema#string

P2888

P304

41-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.481

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019734993

http://www.w3.org/2001/XMLSchema#string

P698

21113169

http://www.w3.org/2001/XMLSchema#string